KRON Key Statistics, Chart & Performance
The current stock price of KRON is 0.88 USD. In the past month the price increased by 31.15%. In the past year, price decreased by -18.52%.
KRON Latest News, Press Relases and Analysis
KRON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About KRON
Company Profile
Kronos Bio, Inc. is a clinical development biopharmaceutical company. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. The company is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. The company has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. The company is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Company Info
KRONOS BIO INC
1300 S. El Camino Real, Suite 400
San Mateo CALIFORNIA 94402 US
CEO: Norbert Bischofberger
Employees: 10
Phone: 16507815200
KRONOS BIO INC / KRON FAQ
What does KRON do?
Kronos Bio, Inc. is a clinical development biopharmaceutical company. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. The company is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. The company has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. The company is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
What is the current price of KRON stock?
The current stock price of KRON is 0.88 USD. The price increased by 1.49% in the last trading session.
Does KRON stock pay dividends?
KRON does not pay a dividend.
What is the ChartMill rating of KRONOS BIO INC stock?
KRON has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for KRON stock?
The Revenue of KRONOS BIO INC (KRON) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of KRONOS BIO INC (KRON)?
You can find the ownership structure of KRONOS BIO INC (KRON) on the Ownership tab.
KRON Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to KRON. When comparing the yearly performance of all stocks, KRON is a bad performer in the overall market: 78.82% of all stocks are doing better.
KRON Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRON. No worries on liquidiy or solvency for KRON as it has an excellent financial health rating, but there are worries on the profitability.
KRON Financial Highlights
Over the last trailing twelve months KRON reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 46.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.63% | ||
| ROE | -80.8% | ||
| Debt/Equity | 0 |
KRON Forecast & Estimates
7 analysts have analysed KRON and the average price target is 2.3 USD. This implies a price increase of 160.8% is expected in the next year compared to the current price of 0.88.